Cargando…

Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1

BACKGROUND: Treatment for children with high-risk neuroblastoma with anti-disialoganglioside mAb ch14.18, IL-2, and GM-CSF plus 13-cis-retinoic acid after myeloablative chemotherapy improves survival, but 40 % of patients still relapse during or after this therapy. The microenvironment of high-risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yibing, Sun, Jianping, Sheard, Michael A., Tran, Hung C., Wan, Zesheng, Liu, Wei Yao, Asgharzadeh, Shahab, Sposto, Richard, Wu, Hong Wei, Seeger, Robert C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907789/ https://www.ncbi.nlm.nih.gov/pubmed/23982484 http://dx.doi.org/10.1007/s00262-013-1466-y

Ejemplares similares

Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2
por: Metelitsa, Leonid S., et al.
Publicado: (2004)

Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
por: Zobel, Michael John, et al.
Publicado: (2020)

Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC
por: Hadjidaniel, Michael D., et al.
Publicado: (2017)

Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF-β/IL-6 pathway in neuroblastoma
por: Louault, Kevin, et al.
Publicado: (2022)

An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment
por: DePeaux, Kristin, et al.
Publicado: (2023)

Lenalidomide overcomes the immunosuppression of regulatory CD8(+)CD28(−) T-cells
por: Neuber, Brigitte, et al.
Publicado: (2017)

Involvement of IL-10 and TGF-β in HLA-E-mediated neuroblastoma migration and invasion
por: Zhen, Zijun, et al.
Publicado: (2016)

Immunosuppressive Microenvironment in Neuroblastoma
por: Pistoia, Vito, et al.
Publicado: (2013)

Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma
por: Lascano, Danny, et al.
Publicado: (2023)

Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
por: Orienti, Isabella, et al.
Publicado: (2020)

A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment
por: Shim, Jenny, et al.
Publicado: (2021)

Exploring and Targeting the Tumor Immune Microenvironment of Neuroblastoma
por: Masih, Katherine E., et al.
Publicado: (2021)

Enhancing Natural Killer and CD8(+) T Cell-Mediated Anticancer Cytotoxicity and Proliferation of CD8(+) T Cells with HLA-E Monospecific Monoclonal Antibodies
por: Ravindranath, Mepur H., et al.
Publicado: (2019)

Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma
por: Lopez, Gonzalo, et al.
Publicado: (2020)

Artificial Tumor Microenvironments in Neuroblastoma
por: Quinn, Colin H., et al.
Publicado: (2021)

Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma
por: Shirinbak, Soheila, et al.
Publicado: (2021)

Genome wide DNA methylation analysis identifies novel molecular subgroups and predicts survival in neuroblastoma
por: Lalchungnunga, H., et al.
Publicado: (2022)

B-cell acute lymphoblastic leukemia promotes an immune suppressive microenvironment that can be overcome by IL-12
por: Hunter, Rae, et al.
Publicado: (2022)

A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model
por: Orienti, Isabella, et al.
Publicado: (2019)

Natural Killer Cell Cytotoxicity and Immunosuppressive Cytokines (IL-10, TGF-β1) in Patients with Gastric Cancer
por: Szkaradkiewicz, Andrzej, et al.
Publicado: (2010)

The genetic landscape of high-risk neuroblastoma
por: Pugh, Trevor J., et al.
Publicado: (2013)

Low Expression of IL-15 and NKT in Tumor Microenvironment Predicts Poor Outcome of MYCN-Non-Amplified Neuroblastoma
por: Liao, Yu-Mei, et al.
Publicado: (2021)

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells
por: Richardson, Kelden, et al.
Publicado: (2022)

Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
por: Thangaraj, Jaya Lakshmi, et al.
Publicado: (2022)

Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.
por: Foreman, N. K., et al.
Publicado: (1993)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

Natural Killer Cell Deficiency in Neuroblastoma Amplified Sequence Gene Mutation
por: Albar, Rawia F, et al.
Publicado: (2021)

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
por: Moghimi, Babak, et al.
Publicado: (2021)

Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
por: Borankova, Karolina, et al.
Publicado: (2023)

One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy
por: Besson, Laurie, et al.
Publicado: (2018)

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
por: Capasso, Mario, et al.
Publicado: (2009)

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
por: Barker, S E, et al.
Publicado: (2007)

Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses
por: Earl, Patricia L., et al.
Publicado: (2020)

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
por: Geyer, Mark B., et al.
Publicado: (2023)

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
por: Albertsson-Lindblad, Alexandra, et al.
Publicado: (2019)

Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment
por: Sun, Bo, et al.
Publicado: (2020)

Editorial: Overcoming the Immune Microenvironment of Hepatocellular Cancer
por: Shetty, Shishir, et al.
Publicado: (2021)

Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Strategies to overcome DC dysregulation in the tumor microenvironment
por: Mestrallet, Guillaume, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vrqovciv7jb7bqec58r2s13hqc